SG10201811475YA - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) - Google Patents

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Info

Publication number
SG10201811475YA
SG10201811475YA SG10201811475YA SG10201811475YA SG10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA
Authority
SG
Singapore
Prior art keywords
methods
antibodies
receptor
stimulating factor
colony stimulating
Prior art date
Application number
SG10201811475YA
Inventor
Julie Hambleton
Emma Masteller
James Zanghi
Robert Sikorski
Hong Xiang
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of SG10201811475YA publication Critical patent/SG10201811475YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSFIR) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis. [No suitable figure]
SG10201811475YA 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) SG10201811475YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462015710P 2014-06-23 2014-06-23

Publications (1)

Publication Number Publication Date
SG10201811475YA true SG10201811475YA (en) 2019-02-27

Family

ID=53674259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201610672YA SG11201610672YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201811475YA SG10201811475YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201610672YA SG11201610672YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Country Status (13)

Country Link
US (2) US10975153B2 (en)
EP (1) EP3157957A1 (en)
JP (2) JP6964410B2 (en)
KR (2) KR20170016501A (en)
CN (2) CN106795222A (en)
AU (1) AU2015280362B2 (en)
BR (1) BR112016029460A2 (en)
CA (1) CA2951156A1 (en)
EA (1) EA037561B1 (en)
IL (1) IL249393B (en)
MX (1) MX2016016664A (en)
SG (2) SG11201610672YA (en)
WO (1) WO2015200089A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN110709422B (en) * 2017-04-19 2023-12-26 马伦戈治疗公司 Multispecific molecules and uses thereof
CN109053887B (en) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 A kind of anti-human CSF-1R monoclonal antibody and purposes
CN108948199B (en) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application thereof
JP2021534101A (en) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Oligonucleotide compositions for targeting CCR2 and CSF1R and their use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989003687A1 (en) 1987-10-23 1989-05-05 Genetics Institute, Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69329247T2 (en) 1992-06-09 2001-05-31 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville CRYSTALIZATION OF M-CSF
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10218791A (en) 1997-01-31 1998-08-18 Toagosei Co Ltd Therapeutic agent of chronic rheumatoid arthritis
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd Betacellulin protein-containing preparations
JP2002544174A (en) 1999-05-07 2002-12-24 ジェネンテック・インコーポレーテッド Treatment of autoimmune diseases using antagonists that bind to B cell surface markers
JP4307775B2 (en) 1999-10-28 2009-08-05 ゼイェトホサイン・アハリネヤート Use of CSF-1 inhibitors
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1572106B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CN1871359B (en) 2003-10-22 2010-11-17 凯克研究生院 Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005070447A2 (en) 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
AU2005245896A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CA2574654C (en) 2004-07-22 2014-02-18 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2008528033A (en) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス， インコーポレイテッド Leader sequence for detecting secretion of a polypeptide and method for its production
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CN101384621A (en) 2005-11-10 2009-03-11 受体生物公司 Methods for production of receptor and ligand isoforms
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
CN101379400A (en) 2005-12-22 2009-03-04 诺华有限公司 Soluble human M-CSF receptor and uses thereof
WO2007081879A2 (en) 2006-01-05 2007-07-19 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2649962A1 (en) 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
CL2008002444A1 (en) 2007-08-21 2009-09-04 Amgen Inc Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
JP2011502266A (en) 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Biomarkers to assess response to FMS treatment
JPWO2009075344A1 (en) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター MLL leukemia and MOZ leukemia therapeutic agent using M-CSF receptor as molecular target, and use thereof
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
NZ587830A (en) 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
NZ599516A (en) 2009-12-10 2013-11-29 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CN102918060B (en) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 Anti-human CSF-1R antibody and uses thereof
JP5989547B2 (en) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antibody to human CSF-1R and use thereof
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
TR201900368T4 (en) * 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Antibodies that bind to Csf1r.
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
BR112014008540A2 (en) 2011-10-21 2020-12-01 Transgène S.A. method to increase m1 macrophage clustering in a patient
WO2013057290A1 (en) 2011-10-21 2013-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
RU2670743C9 (en) * 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014036357A1 (en) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA2963147A1 (en) * 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer

Also Published As

Publication number Publication date
KR20230086809A (en) 2023-06-15
CN106795222A (en) 2017-05-31
SG11201610672YA (en) 2017-01-27
EA037561B1 (en) 2021-04-14
US20210317219A1 (en) 2021-10-14
IL249393A0 (en) 2017-02-28
JP2020169179A (en) 2020-10-15
JP6964410B2 (en) 2021-11-10
AU2015280362B2 (en) 2021-03-04
CA2951156A1 (en) 2015-12-30
US10975153B2 (en) 2021-04-13
JP2017520562A (en) 2017-07-27
KR20170016501A (en) 2017-02-13
MX2016016664A (en) 2017-03-20
EP3157957A1 (en) 2017-04-26
EA201692482A1 (en) 2017-05-31
US20170152320A1 (en) 2017-06-01
IL249393B (en) 2022-02-01
BR112016029460A2 (en) 2017-10-24
CN113350501A (en) 2021-09-07
WO2015200089A1 (en) 2015-12-30
AU2015280362A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
SG10201906328RA (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12019502283A1 (en) Anti-lag3 antibodies
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
MX2020004229A (en) Methods of making chimeric antigen receptor-expressing cells.
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2017008218A (en) Anti-csf1r antibodies for treating pvns.
PH12017501042A1 (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
MX2016016886A (en) Anti-axl antibodies.
PH12014501758B1 (en) Cd47 antibodies and methods of use thereof
MX2017007941A (en) Anti-axl antagonistic antibodies.
MX2016016883A (en) Anti-axl antibodies.
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
PH12016501366A1 (en) Novel anti-baff antibodies
MX2017007491A (en) Blood brain barrier receptor antibodies and methods of use.
SG10201811475YA (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
EA201691112A1 (en) FORMATION OF EX VITO ANTIBODIES